JAK inhibitors

Sanofi
Favicon Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Sanofi is committing $1.53 billion to license a first-in-class JAK/ROCK inhibitor from Sino Biopharm with eyes on both hematology and immunology.
Angus Liu Mar 4, 2026 3:00am
Close up shot of the target from a dart game

Lynk sees ph. 3 eczema win as proof of JAK inhibitor's potential

Mar 2, 2026 8:55am
business targets illustration

Lynk targets the JAK pot with phase 3 rheumatoid arthritis win

Jan 12, 2026 8:45am
money flying in

Minghui raises $131M to fund JAK inhibitor launch, ADC trials

Aug 7, 2025 8:15am
photo of a pair of binoculars perched on a rock aimed at the rising sun
Favicon Fierce Pharma

New Incyte CEO takes 'fresh look' at business, outlines BD plan

Aug 4, 2025 11:16am
target reach ladder climb meet win beat competition

Soterios looks to ph. 3 after win for alopecia areata cream

May 30, 2024 8:14am